ID LYN_HUMAN Reviewed; 491 AA. AC P07948-2; DT 01-AUG-1988, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 3. DT 27-MAR-2024, entry version 260. DE RecName: Full=Isoform 2 of Tyrosine-protein kinase Lyn; DE EC=2.7.10.2; DE AltName: Full=Lck/Yes-related novel protein tyrosine kinase; DE AltName: Full=V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; DE AltName: Full=p53Lyn; DE AltName: Full=p56Lyn; GN Name=LYN; Synonyms=JTK8; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY. RX PubMed=3561390; DOI=10.1128/mcb.7.1.237-243.1987; RA Yamanashi Y., Fukushige S., Semba K., Sukegawa J., Miyajima N., RA Matsubara K., Yamamoto T., Toyoshima K.; RT "The yes-related cellular gene lyn encodes a possible tyrosine kinase RT similar to p56lck."; RL Mol. Cell. Biol. 7:237-243(1987). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING. RX PubMed=8125304; DOI=10.1016/0378-1119(94)90811-7; RA Rider L.G., Raben N., Miller L., Jelsema C.; RT "The cDNAs encoding two forms of the LYN protein tyrosine kinase are RT expressed in rat mast cells and human myeloid cells."; RL Gene 138:219-222(1994). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 369-424. RX PubMed=2247464; DOI=10.1073/pnas.87.22.8913; RA Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.; RT "Putative tyrosine kinases expressed in K-562 human leukemia cells."; RL Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 369-424. RX PubMed=1510669; DOI=10.1016/s0006-291x(05)81562-1; RA Bielke W., Ziemiecki A., Kappos L., Miescher G.C.; RT "Expression of the B cell-associated tyrosine kinase gene Lyn in primary RT neuroblastoma tumours and its modulation during the differentiation of RT neuroblastoma cell lines."; RL Biochem. Biophys. Res. Commun. 186:1403-1409(1992). RN [6] RP FUNCTION IN CD19 PHOSPHORYLATION, AND INTERACTION WITH CD19. RX PubMed=7687428; DOI=10.1006/bbrc.1993.1807; RA Roifman C.M., Ke S.; RT "CD19 is a substrate of the antigen receptor-associated protein tyrosine RT kinase in human B cells."; RL Biochem. Biophys. Res. Commun. 194:222-225(1993). RN [7] RP CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND INTERACTION WITH HCLS1. RX PubMed=7682714; DOI=10.1073/pnas.90.8.3631; RA Yamanashi Y., Okada M., Semba T., Yamori T., Umemori H., Tsunasawa S., RA Toyoshima K., Kitamura D., Watanabe T., Yamamoto T.; RT "Identification of HS1 protein as a major substrate of protein-tyrosine RT kinase(s) upon B-cell antigen receptor-mediated signaling."; RL Proc. Natl. Acad. Sci. U.S.A. 90:3631-3635(1993). RN [8] RP INTERACTION WITH FCGR1A, CATALYTIC ACTIVITY, TISSUE SPECIFICITY, AND RP PHOSPHORYLATION. RX PubMed=8064233; DOI=10.1084/jem.180.3.1165; RA Wang A.V., Scholl P.R., Geha R.S.; RT "Physical and functional association of the high affinity immunoglobulin G RT receptor (Fc gamma RI) with the kinases Hck and Lyn."; RL J. Exp. Med. 180:1165-1170(1994). RN [9] RP PHOSPHORYLATION AT TYR-397 AND TYR-508, AND ACTIVITY REGULATION. RX PubMed=7935444; DOI=10.1128/mcb.14.11.7306-7313.1994; RA Hata A., Sabe H., Kurosaki T., Takata M., Hanafusa H.; RT "Functional analysis of Csk in signal transduction through the B-cell RT antigen receptor."; RL Mol. Cell. Biol. 14:7306-7313(1994). RN [10] RP INTERACTION WITH EPSTEIN-BARR VIRUS LMP2A (MICROBIAL INFECTION). RX PubMed=7895172; DOI=10.1016/s1074-7613(95)80040-9; RA Miller C.L., Burkhardt A.L., Lee J.H., Stealey B., Longnecker R., RA Bolen J.B., Kieff E.; RT "Integral membrane protein 2 of Epstein-Barr virus regulates reactivation RT from latency through dominant negative effects on protein-tyrosine RT kinases."; RL Immunity 2:155-166(1995). RN [11] RP PHOSPHORYLATION AT TYR-508 BY MATK. RC TISSUE=Platelet; RX PubMed=9171348; DOI=10.1093/emboj/16.9.2342; RA Hirao A., Hamaguchi I., Suda T., Yamaguchi N.; RT "Translocation of the Csk homologous kinase (Chk/Hyl) controls activity of RT CD36-anchored Lyn tyrosine kinase in thrombin-stimulated platelets."; RL EMBO J. 16:2342-2351(1997). RN [12] RP FUNCTION, INTERACTION WITH NEDD9 AND BCAR1, AND PHOSPHORYLATION. RX PubMed=9020138; DOI=10.1074/jbc.272.7.4230; RA Manie S.N., Beck A.R.P., Astier A., Law S.F., Canty T., Hirai H., RA Druker B.J., Avraham H., Haghayeghi N., Sattler M., Salgia R., RA Griffin J.D., Golemis E.A., Freedman A.S.; RT "Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, RT in a cytoskeleton-dependent signaling pathway initiated by ligation of RT integrin or antigen receptor on human B cells."; RL J. Biol. Chem. 272:4230-4236(1997). RN [13] RP INTERACTION WITH FCGR2B. RX PubMed=9232445; DOI=10.1016/s0165-2478(97)00055-2; RA Sarmay G., Koncz G., Pecht I., Gergely J.; RT "Fc gamma receptor type IIb induced recruitment of inositol and protein RT phosphatases to the signal transductory complex of human B-cell."; RL Immunol. Lett. 57:159-164(1997). RN [14] RP INTERACTION WITH KIT, AND PHOSPHORYLATION. RX PubMed=9341198; DOI=10.1074/jbc.272.43.27450; RA Linnekin D., DeBerry C.S., Mou S.; RT "Lyn associates with the juxtamembrane region of c-Kit and is activated by RT stem cell factor in hematopoietic cell lines and normal progenitor cells."; RL J. Biol. Chem. 272:27450-27455(1997). RN [15] RP FUNCTION IN DNA DAMAGE RESPONSE; APOPTOSIS AND PHOSPHORYLATION OF RP PTPN6/SHPTP1, AND INTERACTION WITH PTPN6/SHPTP1. RX PubMed=10574931; DOI=10.1074/jbc.274.49.34663; RA Yoshida K., Kharbanda S., Kufe D.; RT "Functional interaction between SHPTP1 and the Lyn tyrosine kinase in the RT apoptotic response to DNA damage."; RL J. Biol. Chem. 274:34663-34668(1999). RN [16] RP INTERACTION WITH CBLC. RX PubMed=10362357; DOI=10.1038/sj.onc.1202753; RA Keane M.M., Ettenberg S.A., Nau M.M., Banerjee P., Cuello M., Penninger J., RA Lipkowitz S.; RT "cbl-3: a new mammalian cbl family protein."; RL Oncogene 18:3365-3375(1999). RN [17] RP FUNCTION IN CD79A PHOSPHORYLATION, AND INTERACTION WITH CD79A. RX PubMed=10748115; DOI=10.1074/jbc.m909044199; RA Gaul B.S., Harrison M.L., Geahlen R.L., Burton R.A., Post C.B.; RT "Substrate recognition by the Lyn protein-tyrosine kinase. NMR structure of RT the immunoreceptor tyrosine-based activation motif signaling region of the RT B cell antigen receptor."; RL J. Biol. Chem. 275:16174-16182(2000). RN [18] RP FUNCTION IN REGULATION OF MAST CELL PROLIFERATION, AND MUTAGENESIS OF RP LYS-275. RX PubMed=11435302; DOI=10.1182/blood.v98.2.343; RA O'Laughlin-Bunner B., Radosevic N., Taylor M.L., Shivakrupa R., DeBerry C., RA Metcalfe D.D., Zhou M., Lowell C., Linnekin D.; RT "Lyn is required for normal stem cell factor-induced proliferation and RT chemotaxis of primary hematopoietic cells."; RL Blood 98:343-350(2001). RN [19] RP INTERACTION WITH PDE4A. RC TISSUE=Brain; RX PubMed=11306681; DOI=10.1124/mol.59.5.996; RA Rena G., Begg F., Ross A., MacKenzie C., McPhee I., Campbell L., Huston E., RA Sullivan M., Houslay M.D.; RT "Molecular cloning, genomic positioning, promoter identification, and RT characterization of the novel cyclic AMP-specific phosphodiesterase RT PDE4A10."; RL Mol. Pharmacol. 59:996-1011(2001). RN [20] RP FUNCTION. RX PubMed=10891478; DOI=10.1128/mcb.20.15.5370-5380.2000; RA Yoshida K., Weichselbaum R., Kharbanda S., Kufe D.; RT "Role for Lyn tyrosine kinase as a regulator of stress-activated protein RT kinase activity in response to DNA damage."; RL Mol. Cell. Biol. 20:5370-5380(2000). RN [21] RP FUNCTION IN DNA DAMAGE RESPONSE; APOPTOSIS AND PHOSPHORYLATION OF PPP1R15A, RP INTERACTION WITH PPP1R15A, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-275. RX PubMed=11517336; DOI=10.1073/pnas.191130798; RA Grishin A.V., Azhipa O., Semenov I., Corey S.J.; RT "Interaction between growth arrest-DNA damage protein 34 and Src kinase Lyn RT negatively regulates genotoxic apoptosis."; RL Proc. Natl. Acad. Sci. U.S.A. 98:10172-10177(2001). RN [22] RP FUNCTION IN PHOSPHORYLATION OF KIT AND DOK1, CATALYTIC ACTIVITY, AND RP INTERACTION WITH KIT. RX PubMed=11825908; DOI=10.1074/jbc.m200277200; RA Liang X., Wisniewski D., Strife A., Shivakrupa R., Clarkson B., Resh M.D.; RT "Phosphatidylinositol 3-kinase and Src family kinases are required for RT phosphorylation and membrane recruitment of Dok-1 in c-Kit signaling."; RL J. Biol. Chem. 277:13732-13738(2002). RN [23] RP INTERACTION WITH MUC1. RX PubMed=12750561; DOI=10.4161/cbt.2.2.282; RA Li Y., Chen W., Ren J., Yu W.H., Li Q., Yoshida K., Kufe D.; RT "DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin- RT 7."; RL Cancer Biol. Ther. 2:187-193(2003). RN [24] RP INTERACTION WITH UNC119. RX PubMed=12496276; DOI=10.1074/jbc.m208261200; RA Cen O., Gorska M.M., Stafford S.J., Sur S., Alam R.; RT "Identification of UNC119 as a novel activator of SRC-type tyrosine RT kinases."; RL J. Biol. Chem. 278:8837-8845(2003). RN [25] RP FUNCTION IN THPO-MEDIATED CELL PROLIFERATION. RX PubMed=14726379; DOI=10.1182/blood-2003-10-3566; RA Lannutti B.J., Drachman J.G.; RT "Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of RT hematopoietic cell lines and primary megakaryocytic progenitors."; RL Blood 103:3736-3743(2004). RN [26] RP SUBCELLULAR LOCATION, DOMAIN, AND MUTAGENESIS OF LYS-275; ASP-346; GLU-353; RP ASP-498 AND ASP-499. RX PubMed=15173188; DOI=10.1083/jcb.200403011; RA Kasahara K., Nakayama Y., Ikeda K., Fukushima Y., Matsuda D., Horimoto S., RA Yamaguchi N.; RT "Trafficking of Lyn through the Golgi caveolin involves the charged RT residues on alphaE and alphaI helices in the kinase domain."; RL J. Cell Biol. 165:641-652(2004). RN [27] RP REVIEW ON ROLE IN KIT SIGNALING. RX PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055; RA Roskoski R. Jr.; RT "Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor."; RL Biochem. Biophys. Res. Commun. 337:1-13(2005). RN [28] RP FUNCTION IN PHOSPHORYLATION OF HCLS1. RX PubMed=15795233; DOI=10.1074/jbc.m412634200; RA Brunati A.M., Deana R., Folda A., Massimino M.L., Marin O., Ledro S., RA Pinna L.A., Donella-Deana A.; RT "Thrombin-induced tyrosine phosphorylation of HS1 in human platelets is RT sequentially catalyzed by Syk and Lyn tyrosine kinases and associated with RT the cellular migration of the protein."; RL J. Biol. Chem. 280:21029-21035(2005). RN [29] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-508, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=15592455; DOI=10.1038/nbt1046; RA Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., RA Zha X.-M., Polakiewicz R.D., Comb M.J.; RT "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells."; RL Nat. Biotechnol. 23:94-101(2005). RN [30] RP FUNCTION. RX PubMed=16467205; DOI=10.1182/blood-2005-08-3343; RA Nakata Y., Tomkowicz B., Gewirtz A.M., Ptasznik A.; RT "Integrin inhibition through Lyn-dependent cross talk from CXCR4 chemokine RT receptors in normal human CD34+ marrow cells."; RL Blood 107:4234-4239(2006). RN [31] RP INTERACTION WITH ABL1. RX PubMed=16912036; DOI=10.1074/jbc.m605902200; RA Meyn M.A. III, Wilson M.B., Abdi F.A., Fahey N., Schiavone A.P., Wu J., RA Hochrein J.M., Engen J.R., Smithgall T.E.; RT "Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate RT Bcr-Abl transforming activity."; RL J. Biol. Chem. 281:30907-30916(2006). RN [32] RP INTERACTION WITH PAG1, MUTAGENESIS OF TYR-397, CHARACTERIZATION OF VARIANT RP SAIDV PHE-508, ACTIVITY REGULATION, AND UBIQUITINATION. RX PubMed=16920712; DOI=10.1074/jbc.m602637200; RA Ingley E., Schneider J.R., Payne C.J., McCarthy D.J., Harder K.W., RA Hibbs M.L., Klinken S.P.; RT "Csk-binding protein mediates sequential enzymatic down-regulation and RT degradation of Lyn in erythropoietin-stimulated cells."; RL J. Biol. Chem. 281:31920-31929(2006). RN [33] RP INTERACTION WITH TGFB1I1. RX PubMed=17233630; DOI=10.1042/bj20061618; RA Rathore V.B., Okada M., Newman P.J., Newman D.K.; RT "Paxillin family members function as Csk-binding proteins that regulate Lyn RT activity in human and murine platelets."; RL Biochem. J. 403:275-281(2007). RN [34] RP FUNCTION IN PHOSPHORYLATION OF LPXN, AND INTERACTION WITH LPXN. RX PubMed=17640867; DOI=10.1074/jbc.m704625200; RA Chew V., Lam K.P.; RT "Leupaxin negatively regulates B cell receptor signaling."; RL J. Biol. Chem. 282:27181-27191(2007). RN [35] RP INTERACTION WITH TOM1L1, AND FUNCTION IN TOM1L1 PHOSPHORYLATION. RX PubMed=17977829; DOI=10.1074/jbc.m705168200; RA Zhang J., Suzuki K., Hitomi T., Siraganian R.P.; RT "TOM1L1 is a Lyn substrate involved in FcepsilonRI signaling in mast RT cells."; RL J. Biol. Chem. 282:37669-37677(2007). RN [36] RP FUNCTION IN CELL PROLIFERATION AND SURVIVAL, PHOSPHORYLATION, SUBCELLULAR RP LOCATION, AND ROLE IN DISEASE. RX PubMed=18056483; DOI=10.1182/blood-2007-04-082099; RA Dos Santos C., Demur C., Bardet V., Prade-Houdellier N., Payrastre B., RA Recher C.; RT "A critical role for Lyn in acute myeloid leukemia."; RL Blood 111:2269-2279(2008). RN [37] RP FUNCTION, PHOSPHORYLATION AT TYR-397 AND TYR-508, INTERACTION WITH PAG1 AND RP STAT3, AND SUBCELLULAR LOCATION. RX PubMed=18070987; DOI=10.1182/blood-2007-05-090985; RA Tauzin S., Ding H., Khatib K., Ahmad I., Burdevet D., RA van Echten-Deckert G., Lindquist J.A., Schraven B., Din N.U., Borisch B., RA Hoessli D.C.; RT "Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine RT kinase in human B-NHL rafts."; RL Blood 111:2310-2320(2008). RN [38] RP INTERACTION WITH CBL AND BCR-ABL, FUNCTION IN PHOSPHORYLATION OF BCR-ABL, RP AND ROLE IN DISEASE. RX PubMed=18235045; DOI=10.1182/blood-2007-08-109330; RA Wu J., Meng F., Lu H., Kong L., Bornmann W., Peng Z., Talpaz M., RA Donato N.J.; RT "Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein RT stability in imatinib-resistant chronic myelogenous leukemia cells."; RL Blood 111:3821-3829(2008). RN [39] RP SUBCELLULAR LOCATION, MYRISTOYLATION AT GLY-2, PALMITOYLATION AT CYS-3, AND RP MUTAGENESIS OF GLY-2; CYS-3 AND LYS-275. RX PubMed=18817770; DOI=10.1016/j.yexcr.2008.08.019; RA Ikeda K., Nakayama Y., Togashi Y., Obata Y., Kuga T., Kasahara K., RA Fukumoto Y., Yamaguchi N.; RT "Nuclear localization of Lyn tyrosine kinase mediated by inhibition of its RT kinase activity."; RL Exp. Cell Res. 314:3392-3404(2008). RN [40] RP FUNCTION IN ADHESION AND CELL MIGRATION. RX PubMed=18802065; DOI=10.4049/jimmunol.181.7.4632; RA Malik M., Chen Y.-Y., Kienzle M.F., Tomkowicz B.E., Collman R.G., RA Ptasznik A.; RT "Monocyte migration and LFA-1-mediated attachment to brain microvascular RT endothelia is regulated by SDF-1 alpha through Lyn kinase."; RL J. Immunol. 181:4632-4637(2008). RN [41] RP PHOSPHORYLATION AT TYR-193 AND TYR-460, AND ROLE IN DISEASE. RX PubMed=18577747; DOI=10.1093/jnci/djn188; RA Wu J., Meng F., Kong L.Y., Peng Z., Ying Y., Bornmann W.G., Darnay B.G., RA Lamothe B., Sun H., Talpaz M., Donato N.J.; RT "Association between imatinib-resistant BCR-ABL mutation-negative leukemia RT and persistent activation of LYN kinase."; RL J. Natl. Cancer Inst. 100:926-939(2008). RN [42] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Platelet; RX PubMed=18088087; DOI=10.1021/pr0704130; RA Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J., RA Schuetz C., Walter U., Gambaryan S., Sickmann A.; RT "Phosphoproteome of resting human platelets."; RL J. Proteome Res. 7:526-534(2008). RN [43] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; SER-13; TYR-473 AND RP TYR-508, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [44] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [45] RP INTERACTION WITH FASLG. RX PubMed=19807924; DOI=10.1186/1471-2172-10-53; RA Voss M., Lettau M., Janssen O.; RT "Identification of SH3 domain interaction partners of human FasL (CD178) by RT phage display screening."; RL BMC Immunol. 10:53-53(2009). RN [46] RP INTERACTION WITH ADAM15. RX PubMed=19718658; DOI=10.1002/jcb.22317; RA Kleino I., Ortiz R.M., Yritys M., Huovila A.P., Saksela K.; RT "Alternative splicing of ADAM15 regulates its interactions with cellular RT SH3 proteins."; RL J. Cell. Biochem. 108:877-885(2009). RN [47] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; SER-13; SER-228; TYR-306; RP TYR-316; TYR-473 AND TYR-508, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [48] RP FUNCTION IN LTR4 AND LTR6 HETERODIMERIZATION, AND INTERACTION WITH CD36. RX PubMed=20037584; DOI=10.1038/ni.1836; RA Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A., RA Rayner K.J., Boyer L., Zhong R., Frazier W.A., Lacy-Hulbert A., RA El Khoury J., Golenbock D.T., Moore K.J.; RT "CD36 ligands promote sterile inflammation through assembly of a Toll-like RT receptor 4 and 6 heterodimer."; RL Nat. Immunol. 11:155-161(2010). RN [49] RP INTERACTION WITH NDFIP1 AND NDFIP2, AND UBIQUITINATION. RX PubMed=20534535; DOI=10.1073/pnas.0911714107; RA Mund T., Pelham H.R.; RT "Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin RT ligase activators Ndfip1 and Ndfip2."; RL Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010). RN [50] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [51] RP INTERACTION WITH SCIMP. RX PubMed=21930792; DOI=10.1128/mcb.05817-11; RA Draber P., Vonkova I., Stepanek O., Hrdinka M., Kucova M., Skopcova T., RA Otahal P., Angelisova P., Horejsi V., Yeung M., Weiss A., Brdicka T.; RT "SCIMP, a transmembrane adapter protein involved in major RT histocompatibility complex class II signaling."; RL Mol. Cell. Biol. 31:4550-4562(2011). RN [52] RP REVIEW. RX PubMed=15220000; DOI=10.1016/j.molimm.2004.04.010; RA Lowell C.A.; RT "Src-family kinases: rheostats of immune cell signaling."; RL Mol. Immunol. 41:631-643(2004). RN [53] RP REVIEW ON ROLE IN B CELLS. RX PubMed=15489917; DOI=10.1038/sj.onc.1208075; RA Gauld S.B., Cambier J.C.; RT "Src-family kinases in B-cell development and signaling."; RL Oncogene 23:8001-8006(2004). RN [54] RP REVIEW ON ROLE IN B CELLS. RX PubMed=15664155; DOI=10.1016/j.immuni.2004.12.004; RA Xu Y., Harder K.W., Huntington N.D., Hibbs M.L., Tarlinton D.M.; RT "Lyn tyrosine kinase: accentuating the positive and the negative."; RL Immunity 22:9-18(2005). RN [55] RP REVIEW ON ROLE IN GROWTH FACTOR SIGNALING. RX PubMed=16801133; DOI=10.1080/08977190600581327; RA Hibbs M.L., Harder K.W.; RT "The duplicitous nature of the Lyn tyrosine kinase in growth factor RT signaling."; RL Growth Factors 24:137-149(2006). RN [56] RP REVIEW ON ROLE IN MAST CELLS. RX PubMed=18772004; DOI=10.1016/s0065-2776(08)00403-3; RA Rivera J., Fierro N.A., Olivera A., Suzuki R.; RT "New insights on mast cell activation via the high affinity receptor for RT IgE."; RL Adv. Immunol. 98:85-120(2008). RN [57] RP ROLE IN MYELOID CELL FUNCTION, AND SIGNALING. RX PubMed=19290919; DOI=10.1111/j.1600-065x.2008.00758.x; RA Scapini P., Pereira S., Zhang H., Lowell C.A.; RT "Multiple roles of Lyn kinase in myeloid cell signaling and function."; RL Immunol. Rev. 228:23-40(2009). RN [58] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11 AND SER-13, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [59] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11 AND SER-13, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [60] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11 AND SER-13, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [61] RP MYRISTOYLATION AT GLY-2, CLEAVAGE OF INITIATOR METHIONINE, AND RP IDENTIFICATION BY MASS SPECTROMETRY. RX PubMed=25255805; DOI=10.1038/ncomms5919; RA Thinon E., Serwa R.A., Broncel M., Brannigan J.A., Brassat U., Wright M.H., RA Heal W.P., Wilkinson A.J., Mann D.J., Tate E.W.; RT "Global profiling of co- and post-translationally N-myristoylated proteomes RT in human cells."; RL Nat. Commun. 5:4919-4919(2014). RN [62] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=25944712; DOI=10.1002/pmic.201400617; RA Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D., RA Lane L., Bairoch A., Van Dorsselaer A., Carapito C.; RT "N-terminome analysis of the human mitochondrial proteome."; RL Proteomics 15:2519-2524(2015). RN [63] RP STRUCTURE BY NMR OF 61-123 IN COMPLEX WITH SAIMIRIINE HERPESVIRUS 2 RP TYROSINE KINASE INTERACTING PROTEIN (MICROBIAL INFECTION). RX PubMed=11955060; DOI=10.1021/bi015986j; RA Schweimer K., Hoffmann S., Bauer F., Friedrich U., Kardinal C., RA Feller S.M., Biesinger B., Sticht H.; RT "Structural investigation of the binding of a herpesviral protein to the RT SH3 domain of tyrosine kinase Lck."; RL Biochemistry 41:5120-5130(2002). RN [64] RP STRUCTURE BY NMR OF 61-122, AND INTERACTION WITH HERPESVIRUS TYROSINE RP KINASE INTERACTING PROTEIN (MICROBIAL INFECTION). RX PubMed=16155203; DOI=10.1110/ps.051563605; RA Bauer F., Schweimer K., Meiselbach H., Hoffmann S., Rosch P., Sticht H.; RT "Structural characterization of Lyn-SH3 domain in complex with a RT herpesviral protein reveals an extended recognition motif that enhances RT binding affinity."; RL Protein Sci. 14:2487-2498(2005). RN [65] RP X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 233-512 IN COMPLEX WITH RP STAUROSPORINE. RX PubMed=19857964; DOI=10.1016/j.bmcl.2009.10.038; RA Miyano N., Kinoshita T., Nakai R., Kirii Y., Yokota K., Tada T.; RT "Structural basis for the inhibitor recognition of human Lyn kinase RT domain."; RL Bioorg. Med. Chem. Lett. 19:6557-6560(2009). RN [66] RP VARIANT [LARGE SCALE ANALYSIS] TYR-385. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [67] RP INVOLVEMENT IN SAIDV, AND VARIANT SAIDV 508-TYR--PRO-512 DEL. RX DOI=10.1186/1546-0096-12-S1-O25; RA De Jesus A.A., Montealegre G., Liu Y., Marrero B., Kuehn H., Calvo K., RA Rosenzweig S., Fleisher T., Chyi-Chia Lee R., Brundidge A., Chapelle D., RA Huang Y., Brooks S., Moir S., Meffre E., Merchant M., Deng Z., RA Goldbach-Mansky R.; RT "A de novo nonsense mutation in the tyrosine kinase lyn in a patient with RT an early onset autoinflammatory phenotype."; RL Pediatr. Rheumatol. Online J. 12:O25-O25(2014). RN [68] RP VARIANT SAIDV HIS-508, CHARACTERIZATION OF VARIANTS SAIDV 508-TYR--PRO-512 RP DEL; HIS-508 AND PHE-508, AND FUNCTION. RX PubMed=36122175; DOI=10.1002/art.42354; RA Louvrier C., El Khouri E., Grall Lerosey M., Quartier P., Guerrot A.M., RA Bader Meunier B., Chican J., Mohammad M., Assrawi E., Daskalopoulou A., RA Arenas Garcia A., Copin B., Piterboth W., Dastot Le Moal F., Karabina S.A., RA Amselem S., Giurgea I.; RT "De Novo Gain-Of-Function Variations in LYN Associated With an Early-Onset RT Systemic Autoinflammatory Disorder."; RL Arthritis Rheumatol. 75:468-474(2023). RN [69] RP VARIANTS SAIDV 507-GLN--PRO-512 DEL; 508-TYR--PRO-512 DEL AND PHE-508, RP CHARACTERIZATION OF VARIANTS SAIDV 507-GLN--PRO-512 DEL; 508-TYR--PRO-512 RP DEL AND PHE-508, AND FUNCTION. RX PubMed=36932076; DOI=10.1038/s41467-023-36941-y; RA de Jesus A.A., Chen G., Yang D., Brdicka T., Ruth N.M., Bennin D., RA Cebecauerova D., Malcova H., Freeman H., Martin N., Svojgr K., Passo M.H., RA Bhuyan F., Alehashemi S., Rastegar A.T., Uss K., Kardava L., Marrero B., RA Duric I., Omoyinmi E., Peldova P., Lee C.R., Kleiner D.E., Hadigan C.M., RA Hewitt S.M., Pittaluga S., Carmona-Rivera C., Calvo K.R., Shah N., RA Balascakova M., Fink D.L., Kotalova R., Parackova Z., Peterkova L., RA Kuzilkova D., Campr V., Sramkova L., Biancotto A., Brooks S.R., Manes C., RA Meffre E., Harper R.L., Kuehn H., Kaplan M.J., Brogan P., Rosenzweig S.D., RA Merchant M., Deng Z., Huttenlocher A., Moir S.L., Kuhns D.B., Boehm M., RA Skvarova Kramarzova K., Goldbach-Mansky R.; RT "Constitutively active Lyn kinase causes a cutaneous small vessel RT vasculitis and liver fibrosis syndrome."; RL Nat. Commun. 14:1502-1502(2023). CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=LYN A, p56lyn; CC IsoId=P07948-1; Sequence=Displayed; CC Name=2; Synonyms=LYN B, p53lyn; CC IsoId=P07948-2; Sequence=VSP_005002; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR CCDS; CCDS47859.1; -. DR RefSeq; NP_001104567.1; NM_001111097.2. DR ProteomicsDB; 52046; -. DR Ensembl; ENST00000520220.6; ENSP00000428424.1; ENSG00000254087.8. DR Proteomes; UP000005640; Chromosome 8. PE 1: Evidence at protein level; SQ SEQUENCE 491 AA; 56033 MW; D74E4074D4B0C92A CRC64; MGCIKSKGKD SLSDDGVDLK TQPVPESQLL PGQRFQTKDP EEQGDIVVAL YPYDGIHPDD LSFKKGEKMK VLEEHGEWWK AKSLLTKKEG FIPSNYVAKL NTLETEEWFF KDITRKDAER QLLAPGNSAG AFLIRESETL KGSFSLSVRD FDPVHGDVIK HYKIRSLDNG GYYISPRITF PCISDMIKHY QKQADGLCRR LEKACISPKP QKPWDKDAWE IPRESIKLVK RLGAGQFGEV WMGYYNNSTK VAVKTLKPGT MSVQAFLEEA NLMKTLQHDK LVRLYAVVTR EEPIYIITEY MAKGSLLDFL KSDEGGKVLL PKLIDFSAQI AEGMAYIERK NYIHRDLRAA NVLVSESLMC KIADFGLARV IEDNEYTARE GAKFPIKWTA PEAINFGCFT IKSDVWSFGI LLYEIVTYGK IPYPGRTNAD VMTALSQGYR MPRVENCPDE LYDIMKMCWK EKAEERPTFD YLQSVLDDFY TATEGQYQQQ P //